Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

Iris Francesconi - Interim Head, Investor Relations

Chris Posner - President & Chief Executive Officer

Tom Reilly - Chief Financial Officer

Joana Goncalves - Chief Medical Officer.

Conference Call Participants

Joseph Stringer - Needham & Company

Chi Tran - Bank of America

Daniel Wolle - JPMorgan

David Amsellem - Piper Sandler

Sumant Kulkarni - Canaccord

Oren Livnat - H.C. Wainwright

Operator

Good afternoon. My name is May, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics First Quarter 2022 Financial Results and Update Conference Call. All lines have been placed on mute to avoid any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded.

I would now like to introduce Iris Francesconi, Interim Head of Investor Relations from Cara Therapeutics. Ms. Framcesconi, you may begin your call.

Iris Francesconi

Thank you, May, and good afternoon. Just after market closed today, we issued a press release detailing our corporate progress and financial results for the first quarter 2022. The press release can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website.

Participating in today's call are Chris Posner, Cara's President and Chief Executive Officer; Tom Reilly, Cara's Chief Financial Officer; and Dr. Joana Goncalves, Cara's Chief Medical Officer.

Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the company's ability to successfully commercialize KORSUVA injection, including the timing of the product launch; planned future regulatory submissions; and potential future regulatory approvals; the company's ability to maintain coverage and adequate reimbursement of KORSUVA injection; the performance of our commercial partners including Vifor Pharma; expected timing of the initiation, enrollment and data readouts from the company's planned and ongoing clinical trials; the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the company's products candidates; the potential for the company's products candidates to be alternatives in therapeutic areas investigated; despite and growth of the potential markets for current management; the company's expected cash reach and the potential impact of COVID-19 on the company's commercial launch, clinical development, and regulatory timelines and plans.